View Clinical Trial (Medical Research Study)

A Self-Management Program for Adults With Both Schizophrenia and a Co-Occurring Medical Condition - NCT00525304-21201(Clinical Trial 182474)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Baltimore
State:  
MD
Zip Code: 21201
Conditions: Schizophrenia
Purpose: This study will develop and evaluate the effectiveness of a self-management program for adults living with both schizophrenia and a co-occurring medical condition.
Study summary: Schizophrenia is a life-long brain disorder affecting approximately 1 percent of Americans each year. Schizophrenia can be extremely disabling, causing people to hear voices, experience paranoia or hallucinations, and believe that others are controlling their thoughts. People with schizophrenia also experience increased rates of concurrent medical conditions, such as diabetes, respiratory illness, and heart disease. This can make holding a job or even caring for oneself very difficult. The purpose of this study is to develop and evaluate a self-management program for adults living with both schizophrenia and a concurrent medical condition. Participants in this open-label study will attend 10 to 16 group sessions led by two group leaders. Group sessions will meet each week for an hour during which participants will learn new skills to help them take responsibility for the daily management of chronic medical conditions. In addition to learning how to communicate more effectively with medical providers, participants will learn about healthy eating, the importance of physical activity, addictive behaviors that can worsen health conditions, and proper use of medications. Homework will be assigned weekly for participants to review skills learned in each session. After each session, participants will complete a survey to evaluate the session's effectiveness. At the end of the study, participants will attend one additional group meeting and an individual interview to discuss the overall effectiveness of the intervention and their experiences in the group sessions. The results of this study will be used to evaluate and improve the self-management program for future use.
Criteria: Inclusion Criteria: - Meets DSM-IV criteria for schizophrenia or schizoaffective disorder - Current documented chart diagnosis of at least one chronic medical condition - Received clinic services for a minimum of 3 months prior to study entry - English-speaking - Willing to use an effective form of birth control throughout the study if sexually active Exclusion Criteria: - History of a serious neurological disorder or head trauma with loss of consciousness - Diagnosed with mental retardation or dementia - Diagnosed with end stage organ disease - Currently receiving chemotherapy and/or radiation treatment for cancer - Received psychiatric hospitalization less than 3 months prior to study entry date - Blind and/or deaf - Pregnant - Infected with HIV with a CD4 count under 350 - Diagnosis of AIDS - Diagnosis of anorexia - Problematic substance use, as defined by a mental health provider - Psychiatric instability, as defined by a mental health provider
Study is available at: Fayette Street Clinics
Baltimore, MD 21201
United States

Primary Contact:
Richard W. Goldberg, PhD
Email: rgoldber@psych.umaryland.edu
Phone: 410-706-8473

Secondary Contact:
Richard W. Goldberg, PhD
Email: rgoldber@psych.umaryland.edu
Phone: 410-706-8473
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 22, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.